Research LettersRisk of acute coronary events and serum concentration of asymmetrical dimethylarginine
References (5)
- et al.
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
Lancet
(1992) - et al.
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia
Circulation
(1998)
There are more references available in the full text version of this article.
Cited by (531)
Nitric Oxide Precursors and Dimethylarginines as Risk Markers for Accelerated Measured GFR Decline in the General Population
2023, Kidney International ReportsAssessing the nitric oxide and asymmetric dimethylarginine levels in lifelong premature ejaculation: A prospective study
2022, Revista Internacional de AndrologiaUremic Toxicity
2022, Handbook of Dialysis TherapyA preliminary study on the relationship between sleep, depression and cardiovascular dysfunction in a 4 sample population
2021, IJC Heart and VasculatureCitation Excerpt :Nitric oxide synthase inhibition, another symptom of SDB, may also be partially responsible for downstream irregularities contributing to CVD and MDD pathogenesis. The nitric oxide synthesis inhibitors asymmetrical dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) have been linked to increased inflammation, endothelial damage, and acute coronary heart events [9,14–16]. ADMA and SDMA production also acts as a competing pathway for the conversion of L-arginine to nitric oxide (Fig. 1), contributing to the onset of depression through competitive inhibition that alters arginine bioavailability [17].
Maternal exposure to ambient air pollution and congenital heart defects in China
2021, Environment International
Copyright © 2001 Elsevier Ltd. All rights reserved.